Medium Evidence Level Drugs
Candidates with preliminary evidence requiring further validation
Evidence Standards
| Level | Definition | Clinical Significance |
|---|---|---|
| L3 | Observational studies / Large case series | Preliminary evidence, needs RCT |
| L4 | Preclinical / Mechanistic / Case reports | Mechanism reasonable, lacks clinical validation |
Drug List
L3 Level (55 drugs)
| Drug Name | Indications | Link |
|---|---|---|
| Acetylsalicylic Acid | 10 | View Report |
| Adalimumab | 10 | View Report |
| Alectinib | 10 | View Report |
| Amikacin | 10 | View Report |
| Belatacept | 10 | View Report |
| Bempedoic Acid | 10 | View Report |
| Bexarotene | 10 | View Report |
| Cabozantinib | 10 | View Report |
| Cenobamate | 10 | View Report |
| Cytarabine | 10 | View Report |
| Daratumumab | 10 | View Report |
| Daunorubicin | 10 | View Report |
| Decitabine | 10 | View Report |
| Elotuzumab | 10 | View Report |
| Emtricitabine | 10 | View Report |
| Enalapril | 10 | View Report |
| Enfuvirtide | 10 | View Report |
| Eptifibatide | 10 | View Report |
| Eptinezumab | 10 | View Report |
| Ertapenem | 10 | View Report |
| Fenofibrate | 10 | View Report |
| Fondaparinux | 10 | View Report |
| Fremanezumab | 10 | View Report |
| Idelalisib | 10 | View Report |
| Inebilizumab | 10 | View Report |
| Interferon Beta-1B | 10 | View Report |
| Ivabradine | 10 | View Report |
| Ixazomib | 10 | View Report |
| Ketoconazole | 10 | View Report |
| Lacosamide | 10 | View Report |
| Laronidase | 10 | View Report |
| Larotrectinib | 10 | View Report |
| Levetiracetam | 10 | View Report |
| Linaclotide | 10 | View Report |
| Melatonin | 10 | View Report |
| Meropenem | 10 | View Report |
| Mexiletine | 10 | View Report |
| Micafungin | 10 | View Report |
| Neratinib | 10 | View Report |
| Nitisinone | 10 | View Report |
| Omalizumab | 10 | View Report |
| Ozanimod | 10 | View Report |
| Parecoxib | 10 | View Report |
| Pazopanib | 10 | View Report |
| Posaconazole | 10 | View Report |
| Pravastatin | 10 | View Report |
| Selexipag | 10 | View Report |
| Selinexor | 10 | View Report |
| Siltuximab | 10 | View Report |
| Temoporfin | 10 | View Report |
| Tocilizumab | 10 | View Report |
| Tofacitinib | 10 | View Report |
| Trastuzumab Emtansine | 10 | View Report |
| Vortioxetine | 10 | View Report |
| Zoledronic Acid | 10 | View Report |
L4 Level (88 drugs)
| Drug Name | Indications | Link |
|---|---|---|
| Abatacept | 10 | View Report |
| Abemaciclib | 10 | View Report |
| Ambrisentan | 10 | View Report |
| Anagrelide | 10 | View Report |
| Apixaban | 10 | View Report |
| Avanafil | 10 | View Report |
| Avelumab | 10 | View Report |
| Bedaquiline | 10 | View Report |
| Bictegravir | 10 | View Report |
| Bosentan | 10 | View Report |
| Brexpiprazole | 10 | View Report |
| Brimonidine | 10 | View Report |
| Brivaracetam | 10 | View Report |
| Budesonide | 10 | View Report |
| Buprenorphine | 10 | View Report |
| Certolizumab Pegol | 10 | View Report |
| Cholic Acid | 10 | View Report |
| Daptomycin | 10 | View Report |
| Deferasirox | 10 | View Report |
| Deferiprone | 10 | View Report |
| Delamanid | 10 | View Report |
| Dolutegravir | 10 | View Report |
| Doravirine | 10 | View Report |
| Dupilumab | 10 | View Report |
| Duvelisib | 10 | View Report |
| Efavirenz | 10 | View Report |
| Eliglustat | 10 | View Report |
| Eltrombopag | 10 | View Report |
| Entacapone | 10 | View Report |
| Entecavir | 10 | View Report |
| Entrectinib | 10 | View Report |
| Erlotinib | 10 | View Report |
| Esketamine | 10 | View Report |
| Etanercept | 10 | View Report |
| Filgrastim | 10 | View Report |
| Gemtuzumab Ozogamicin | 10 | View Report |
| Glecaprevir | 10 | View Report |
| Glucagon | 10 | View Report |
| Glycopyrronium | 10 | View Report |
| Golimumab | 10 | View Report |
| Grazoprevir | 10 | View Report |
| Human Thrombin | 10 | View Report |
| Icosapent Ethyl | 10 | View Report |
| Imatinib | 10 | View Report |
| Imiglucerase | 10 | View Report |
| Inotersen | 10 | View Report |
| Irbesartan | 10 | View Report |
| Isatuximab | 10 | View Report |
| Ivacaftor | 10 | View Report |
| Ixekizumab | 10 | View Report |
| Lopinavir | 10 | View Report |
| Mannitol | 10 | View Report |
| Mepolizumab | 10 | View Report |
| Mometasone | 10 | View Report |
| Netarsudil | 10 | View Report |
| Nevirapine | 10 | View Report |
| Nilotinib | 10 | View Report |
| Nintedanib | 10 | View Report |
| Nusinersen | 10 | View Report |
| Palonosetron | 10 | View Report |
| Parathyroid Hormone | 10 | View Report |
| Pertuzumab | 10 | View Report |
| Pitolisant | 10 | View Report |
| Plerixafor | 10 | View Report |
| Pregabalin | 10 | View Report |
| Raltegravir | 10 | View Report |
| Reteplase | 10 | View Report |
| Ribociclib | 10 | View Report |
| Ritonavir | 10 | View Report |
| Rivastigmine | 10 | View Report |
| Roxadustat | 10 | View Report |
| Simoctocog Alfa | 50 | View Report |
| Sofosbuvir | 10 | View Report |
| Teduglutide | 10 | View Report |
| Tenofovir Disoproxil | 10 | View Report |
| Tigecycline | 10 | View Report |
| Timolol | 10 | View Report |
| Tipranavir | 10 | View Report |
| Tirzepatide | 10 | View Report |
| Tobramycin | 10 | View Report |
| Toremifene | 10 | View Report |
| Valsartan | 10 | View Report |
| Velpatasvir | 10 | View Report |
| Venetoclax | 10 | View Report |
| Vernakalant | 10 | View Report |
| Vigabatrin | 10 | View Report |
| Zanubrutinib | 10 | View Report |
| Ziconotide | 10 | View Report |
Criteria for L3-L4 Classification
L3 Requirements
- Cohort or case-control study
- OR large case series (≥50 patients)
- Published results with quantitative outcomes
L4 Requirements
- In vitro or animal studies showing efficacy
- OR mechanistic rationale with supporting data
- OR case reports (< 10 patients)